These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Oral treprostinil for the treatment of pulmonary arterial hypertension. de Lartigue J Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906 [TBL] [Abstract][Full Text] [Related]
11. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621 [TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Langleben D; Barst RJ; Badesch D; Groves BM; Tapson VF; Murali S; Bourge RC; Ettinger N; Shalit E; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Stewart DJ; Long W Circulation; 1999 Jun; 99(25):3266-71. PubMed ID: 10385501 [TBL] [Abstract][Full Text] [Related]
13. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension]. Osvaldo Cáneva J; Ossés JM Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911 [TBL] [Abstract][Full Text] [Related]
14. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Beghetti M Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006 [TBL] [Abstract][Full Text] [Related]
15. Oral treprostinil in the treatment of pulmonary arterial hypertension. Feldman J; Habib N; Radosevich J; Dutt M Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964 [TBL] [Abstract][Full Text] [Related]
16. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents. Yamamoto K; Takeda Y; Takeda Y; Naniwa T; Narita H; Ohte N BMC Res Notes; 2014 Jun; 7():359. PubMed ID: 24920465 [TBL] [Abstract][Full Text] [Related]